Antibe Therapeutics Inc.
ATE
Rang in aandelen
#31789
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Aandeelprijs
$0.21483059
Laatst gesynchroniseerd: 2024-05-07
Marktkapitalisatie
$11.13M
Verandering (1 dag)
0.34%
Verandering (1 jaar)
-0.36%
Land
CA
Handel Antibe Therapeutics Inc. (ATE)
Categorie
Healthcare
Koersgeschiedenis voor Antibe Therapeutics Inc. (ATE)
Hoogste slotkoers: $0.22 op 2025-04-01
Laagste slotkoers: $4.78 op 2014-10-01
Laagste slotkoers: $4.78 op 2014-10-01
Koersgeschiedenis van Antibe Therapeutics Inc. van 2014 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2025 | -0.02% |
| 2024 | -64.79% |
| 2023 | 73.56% |
| 2022 | -33.35% |
| 2021 | -82.11% |
| 2020 | -6.13% |
| 2019 | 60.42% |
| 2018 | 70.25% |
| 2017 | -45.71% |
| 2016 | 86.85% |
| 2015 | -71.73% |
| 2014 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $100.56 | -21.41% |
US
|
|
| $93.07 | -2.95% |
IE
|
|
| $297.13 | -23.49% |
US
|
|
| $44.47 | -57.18% |
US
|
|
| $47.03 | -17.91% |
DE
|
